These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1379149)

  • 1. Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.
    McTavish D; Heel RC
    Drugs; 1992 May; 43(5):713-33. PubMed ID: 1379149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexfenfluramine. Its place in weight control.
    Turner P
    Drugs; 1990; 39 Suppl 3():53-62. PubMed ID: 2197076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexfenfluramine hydrochloride: an anorexigenic agent.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1997 Sep; 54(18):2059-72. PubMed ID: 9377205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A close look at fenfluramine and dexfenfluramine.
    Vivero LE; Anderson PO; Clark RF
    J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
    Mathus-Vliegen EM; van de Voorde K; Kok AM; Res AM
    J Intern Med; 1992 Aug; 232(2):119-27. PubMed ID: 1506807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
    Drent ML; Zelissen PM; Koppeschaar HP; Nieuwenhuyzen Kruseman AC; Lutterman JA; van der Veen EA
    Int J Obes Relat Metab Disord; 1995 May; 19(5):299-304. PubMed ID: 7647820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place of dexfenfluramine in the management of obesity.
    Guy-Grand BJ
    Clin Neuropharmacol; 1988; 11 Suppl 1():S216-23. PubMed ID: 3052820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis.
    Carvajal A; García del Pozo J; Martín de Diego I; Rueda de Castro AM; Velasco A
    Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):285-90. PubMed ID: 11031729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexfenfluramine and appetite in humans.
    Blundell JE; Hill AJ
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S51-9. PubMed ID: 1338323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin and dietary fat intake: effects of dexfenfluramine.
    Blundell JE; Lawton CL
    Metabolism; 1995 Feb; 44(2 Suppl 2):33-7. PubMed ID: 7869935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical studies with dexfenfluramine: from past to future.
    Guy-Grand B
    Obes Res; 1995 Nov; 3 Suppl 4():491S-496S. PubMed ID: 8697048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [International study of the effect of dexfenfluramine in obesity (ISIS): 6 months' results].
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Rev Med Interne; 1989; 10(3):271-7. PubMed ID: 2669089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic abnormalities linked to obesity: effects of dexfenfluramine in the corpulent rat.
    Brindley DN; Russell JC
    Metabolism; 1995 Feb; 44(2 Suppl 2):23-7. PubMed ID: 7869933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
    Finer N; Craddock D; Lavielle R; Keen H
    Clin Neuropharmacol; 1988; 11 Suppl 1():S179-86. PubMed ID: 3052816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Energy expenditure and substrate oxidation rates of obese rats during a 12-day treatment with dexfenfluramine.
    Boschmann M; Aust L; Frenz U; Noack R
    Ann Nutr Metab; 1996; 40(1):10-23. PubMed ID: 8722302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.
    Blanck HM; Khan LK; Serdula MK
    Prev Med; 2004 Dec; 39(6):1243-8. PubMed ID: 15539063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.